Literature DB >> 33999497

Epithelial-to-mesenchymal-like transition events in melanoma.

Dennis Pedri1,2,3, Panagiotis Karras1,2, Ewout Landeloos1,2, Jean-Christophe Marine1,2, Florian Rambow1,2.   

Abstract

Epithelial-to-mesenchymal transition (EMT), a process through which epithelial tumor cells acquire mesenchymal phenotypic properties, contributes to both metastatic dissemination and therapy resistance in cancer. Accumulating evidence indicates that nonepithelial tumors, including melanoma, can also gain mesenchymal-like properties that increase their metastatic propensity and decrease their sensitivity to therapy. In this review, we discuss recent findings, illustrating the striking similarities-but also knowledge gaps-between the biology of mesenchymal-like state(s) in melanoma and mesenchymal state(s) from epithelial cancers. Based on this comparative analysis, we suggest hypothesis-driven experimental approaches to further deepen our understanding of the EMT-like process in melanoma and how such investigations may pave the way towards the identification of clinically relevant biomarkers for prognosis and new therapeutic strategies.
© 2021 Federation of European Biochemical Societies.

Entities:  

Keywords:  EMT; melanoma; phenotype switching

Mesh:

Substances:

Year:  2021        PMID: 33999497     DOI: 10.1111/febs.16021

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  9 in total

1.  BRAF Inhibitors in Melanoma Management: When Friends Become Foes.

Authors:  Gagan Chhabra; Nihal Ahmad
Journal:  J Invest Dermatol       Date:  2021-12-03       Impact factor: 7.590

2.  Epithelial-mesenchymal transition inhibition by metformin reduces melanoma lung metastasis in a murine model.

Authors:  Emerson Soares Veloso; Bárbara Andrade de Carvalho; Felipe Henrique de Souza Silva; Thaís Salviana Ribeiro; Bruna Mendes Lima; Camila Pereira Almeida; Vítor Henrique Soares Romão da Silva; Sara Aparecida Rocha; Marina Rios de Araújo Campos; Helen Lima Del Puerto; Enio Ferreira
Journal:  Sci Rep       Date:  2022-10-22       Impact factor: 4.996

3.  The Expression of Connexin 37, 40, 43, 45 and Pannexin 1 in the Early Human Retina and Choroid Development and Tumorigenesis.

Authors:  Matea Žužul; Mirela Lozić; Natalija Filipović; Samir Čanović; Ana Didović Pavičić; Joško Petričević; Nenad Kunac; Violeta Šoljić; Mirna Saraga-Babić; Suzana Konjevoda; Katarina Vukojevic
Journal:  Int J Mol Sci       Date:  2022-05-25       Impact factor: 6.208

Review 4.  Mechanisms and Clinical Significance of Tumor Lymphatic Invasion.

Authors:  Noriki Fujimoto; Lothar C Dieterich
Journal:  Cells       Date:  2021-09-29       Impact factor: 6.600

5.  Antifibrotic drugs as therapeutic tools in resistant melanoma.

Authors:  Berta Sanchez-Laorden; M Angela Nieto
Journal:  EMBO Mol Med       Date:  2022-02-14       Impact factor: 12.137

6.  ERBB3 binding protein 1 promotes the progression of malignant melanoma through activation of the Wnt/ β-catenin signaling pathway.

Authors:  Yanqiu Bao; Jingshu Cui; Yuyang Yue; Shuxia Cao; Xiangdan Li; Lan Liu
Journal:  Cancer Cell Int       Date:  2022-01-29       Impact factor: 5.722

Review 7.  Cancer Cell Phenotype Plasticity as a Driver of Immune Escape in Melanoma.

Authors:  Valentin Benboubker; Félix Boivin; Stéphane Dalle; Julie Caramel
Journal:  Front Immunol       Date:  2022-03-29       Impact factor: 8.786

Review 8.  Emerging Role of Deubiquitinating Enzymes (DUBs) in Melanoma Pathogenesis.

Authors:  Mickael Ohanna; Pierric Biber; Marcel Deckert
Journal:  Cancers (Basel)       Date:  2022-07-11       Impact factor: 6.575

Review 9.  Role of extracellular matrix architecture and signaling in melanoma therapeutic resistance.

Authors:  Ana Popovic; Sophie Tartare-Deckert
Journal:  Front Oncol       Date:  2022-09-02       Impact factor: 5.738

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.